Clinical Laserthermia Systems Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Clinical Laserthermia Systems şirketinin toplam hissedar öz sermayesi SEK58.2M ve toplam borcu SEK1.2M olup, bu da borç-öz sermaye oranını 2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK68.5M ve SEK10.3M dir.

Anahtar bilgiler

2.0%

Borç/özkaynak oranı

SEK 1.19m

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 15.58m
Eşitlik	SEK 58.20m
Toplam yükümlülükler	SEK 10.28m
Toplam varlıklar	SEK 68.49m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: LS60 'nin kısa vadeli varlıkları ( SEK31.3M ) kısa vadeli yükümlülüklerini ( SEK10.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: LS60 şirketinin kısa vadeli varlıkları ( SEK31.3M ) uzun vadeli yükümlülüklerini ( SEK223.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: LS60 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: LS60 'nin borç/öz sermaye oranı son 5 yılda 99.6% seviyesinden 2% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: LS60 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: LS60 un, serbest nakit akışı her yıl % 12.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Clinical Laserthermia Systems Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released

Clinical Laserthermia Systems AB (publ) Approves Board Appoints

Clinical Laserthermia Systems AB (Publ) Announces Board Resignations

Insufficient new directors

Second quarter 2024 earnings released

New major risk - Shareholder dilution

Clinical Laserthermia Systems AB (publ) Announces Completion of Clinical Study At Skane University Hospital

First quarter 2024 earnings released

Clinical Laserthermia Systems AB (Pub) Announces Two Patients with Localized Prostate Cancer Have Been Safely Treated with the Tranberg Thermal Therapy System At the San Luigi Gonzaga University Hospital in Turin, Italy

Clinical Laserthermia Systems AB (publ) Announces CFO Changes

Clinical Laserthermia Systems AB (publ) Announces Publication of Preclinical Assessment of A Non-Cooled MR Thermometry-Based Neurosurgical Laser Therapy System

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.06 loss per share (vs kr0.85 loss in FY 2022)

Clinical Laserthermia Systems AB (publ) to Report Q2, 2024 Results on Aug 23, 2024

Clinical Laserthermia Systems AB (Publ) Files A New Patent Application for Expanded and Extended Protection of the Company's Technology for Laser-Based Tissue Ablation Until 2044

Clinical Laserthermia Systems AB (publ) Receives Market Approval for Its TRANBERG Portfolio by HSA in Singapore and Initiates the Process of Commercialization in the Region

Clinical Laserthermia Systems AB (publ) Announces Members of the Nomination Committee Appointments

Clinical Laserthermia Systems AB (publ) Announces Executive Changes

Clinical Laserthermia Systems AB (publ) Announces First Patient was Safely Treated with CLS TRANBERG® Thermal Therapy system for laser ablation of Prostate Cancer

High number of new directors

Third quarter 2023 earnings released

Clinical Laserthermia Systems AB (publ) Announces Enrollment Completion of Initial Phase and Extension of Clinical Trial at Radboud University Medical Center

Clinical Laserthermia Systems AB (publ) Announces Resignation of Rolf Ho Bornschein as CFO

Second quarter 2023 earnings released

Clinical Laserthermia Systems AB (publ), Annual General Meeting, Jun 29, 2023

First quarter 2023 earnings released

Clinical Laserthermia Systems AB Appoints Jimmy Johansson as Executive VP Operations

Full year 2022 earnings released: kr0.57 loss per share (vs kr1.11 loss in FY 2021)

Clinical Laserthermia Systems AB (Publ) Announces First Glioblastoma Patient Treated with the Mr-Guided Laser Interstitial Thermal Therapy (MRg LITT) in the Study At Skåne University Hospital

Third quarter 2022 earnings released

High number of new and inexperienced directors

BioStock Studio Announces FDA clearance

Clinical Laserthermia Systems Receives 510(K) Clearance for Its MR Guided Laser Ablation System in Neurosurgery and Initiates Commercialization

Second quarter 2022 earnings released

Clinical Laserthermia Systems AB (publ) Appoints Rolf Ho Bornschein as the New CFO, Effective October 1, 2022 Replacing Lars-Erik Eriksson

Clinical Laserthermia Systems AB (publ) to Report Fiscal Year 2022 Final Results on Feb 23, 2023

Clinical Laserthermia Systems AB (Publ) Appoints Dan J. Mogren as Permanent CEO

Clinical Laserthermia Systems AB's Subsidiary CLS Americas Announces First Patient Treated in Clinical Study Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-To-Intermediate Risk Prostate Cancer

Clinical Laserthermia Systems AB (publ) Releases Ce-Marked New Version of Thermoguide™ Workstation for Use Also with Mri Scanners from GE Healthcare

Clinical Laserthermia Systems AB (Publ) Announces CEO Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clinical Laserthermia Systems AB (publ) Announces CEO Changes

Clinical Laserthermia Systems AB (publ) Files 510 (K) Application with the U.S. Food and Drug Administration for the Second Generation of TRANBERG®

Clinical Laserthermia Systems AB (Publ) Again Releases Tranberg® Sterile Disposable Products on the European Market and Enters into an Agreement with Two Additional Suppliers of Sterilization Services

Third quarter 2021 earnings released

Clinical Laserthermia Systems AB (Publ) to Present TRANBERG® Laser Thermal Therapy System and Latest Enhancements at the 73rd Congress of the German Society for Urology Conference

Second quarter 2021 earnings released

Clinical Laserthermia Systems AB (publ) and Toronto General Hospital Resume Clinical Trial for Prostate Cancer as Company Receives Approval for Updated Sterilization Process by Health Canada

Clinical Laserthermia Systems AB (publ) and University Hospital Magdeburg Obtains the Go for the Investigator Initiated Trial on Focal Laser Ablation Treatment of Localized Prostate Cancer, with the TRANBERG

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.24 loss per share (vs kr1.25 loss in FY 2019)

New 90-day low: €0.39

New 90-day low: €0.42

New 90-day low: €0.45

New 90-day low: €0.59

Clinical Laserthermia Systems AB (Publ) and Toronto General Hospital Continue Clinical Trial Collaboration Regarding MRI-Guided Laser Ablation Treatment of Prostate Cancer

CLS Receives New CPT® Reimbursement Code Approval by American Medical Association for Ultrasound-Guided Focal Laser Ablation of Prostate Cancer

New 90-day low: €0.65

Clinical Laserthermia Systems AB (Publ) and University Hospital Magdeburg Launch Clinical Trial Regarding Focal Laser Ablation Treatment of Localized Prostate Cancer

First half earnings released

New 90-day high - €0.82

New 90-day high - €0.71

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin